Jan Stenvang

Jan Stenvang is an Associate Professor in the Department of Drug Design and Pharmacology at the University of Copenhagen's Faculty of Health and Medical Sciences, specializing in Translational and Clinical Pharmacology. With over 15 years of experience, he has established himself as an expert in cancer resistance mechanisms and biomarker development.

His research focuses on drug resistance in cancer, particularly in colorectal and breast cancer. Dr. Stenvang has developed a research platform using drug-sensitive and drug-resistant cancer cell lines to investigate resistance mechanisms. His work spans biomarker discovery for irinotecan response in colorectal cancer, drug repurposing studies with antihistamines and disulfiram, and novel chemical entities like LMP-400 to overcome resistance. He has contributed to clinical Phase II trials in colorectal and breast cancer guided by predictive biomarkers.

Analysis of his recent publications shows a strong focus on multidrug resistance mechanisms, particularly involving ABCG2/BCRP transporters, and biomarker discovery in various cancer types. His work bridges basic research with clinical applications, emphasizing translational pharmacology approaches to improve cancer treatment outcomes.

Dr. Stenvang has established collaborations with world-leading experts in cancer resistance research, bioinformatics, and systems biology. His laboratory work has led to multiple clinical trial initiatives based on his research findings, demonstrating the translational impact of his work.